A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Not Recruiting

Trial ID: NCT02572167


The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)

Official Title

A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy

Stanford Investigator(s)

Ranjana Advani
Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma

Hans-Christoph Becker, MD, FSABI, FSCCT

Clinical Professor, Radiology


Inclusion Criteria:

   - Relapsed or refractory Hodgkin lymphoma following failure of standard frontline
   chemotherapy for the treatment of classical Hodgkin lymphoma

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

   - Previously treated with brentuximab vedotin, immune-oncology agents, or received an
   allogeneic or autologous stem cell transplant

   - Documented history of a cerebral vascular event

   - History of another invasive malignancy that has not been in remission for at least 3

   - History of progressive multifocal leukoencephalopathy (PML)


drug: brentuximab vedotin

drug: nivolumab

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts

Receive email alerts when trials open to patients.